Supplemental Tables

Supplemental Table 1. Patient and disease characteristics stratified by alloSCT.

Characteristic	No alloSCT (n = 16)	alloSCT (n = 13)	*p*
Age at diagnosis (years)			<0.001
Median	75	63	
Range	50-82	54-70	
Gender, n(%)			0.364
Female	6 (37.5%)	2 (15.4%)	
Male	10 (62.5%)	11 (84.6%)	
Disease, n(%)			0.047
MDS	14 (87.5%)	6 (46.2%)	
AML	2 (12.5%)	7 (53.8%)	
MDS R-IPSS risk*, n = 20(%)			0.967
Low	2 (14.3%)	1 (16.7%)	
Intermediate	9 (64.3%)	4 (66.7%)	
High	3 (21.4%)	1 (16.7%)	
AML ELN risk*, n = 9(%)			NA
Favorable	0	0	
Intermediate	2 (100%)	7 (100%)	
Adverse	0	0	
Karyotype			NA
Normal	13 (81.25%)	13 (100%)	
Abnormal	3 (18.75%)	0	
Complex	0	0	
Abbreviations: R-IPSS: Revised International Prognostic Scoring System, ELN: European Leukemia Network. *Risk stratification at diagnosis.			

Supplemental Table 2. Mutational profile of *DDX41* and other associated pathogenic mutations.

DDX41, pathogenic mutations	VAF range	Number of patients (%)*
c.1574G>A	7-19	9
c.3G>A	48-52	8
c.415_418dup	37-45	5
c.1589G>A	28-46	2
c.260del	7	1
c.1102C>T	49	1
c.121C>T	51	1
c.1588G>A	6	1
c.305_306del	46	1
c.434+1G>A	46	1
c.776A>G	51	1
c.931C>T	48	1
c.946_947del	47	1
DDX41, variance of unknown significance	VAF	Number of patients
c.773C>T	46	2
c.710T>G	46	1
c.517G>A	50	1
c.959C>T	49	1
c.610C>T	40	1
c.622C>G	11	1
c.1032C>G	7	1
Other associated genes with known pathogenic mutations	Gene	Number of patients
	ASXL1	4
	DNMT3A	3
	EZH2	2
	JAK2	1
	NRAS	1
	PHF6	1
	SF3B1	1
Abbreviations: VAF: Variant Allele Frequency		
*Total number is >29 due to few patients having >1 *DDX41* mutations.		

Supplemental Table 3. Patient characteristics, transplant characteristics and transplant outcomes stratified by patient alive or dead at last follow-up.

Characteristic	Alive at last follow-up (n = 8)	Dead at last follow-up (n = 5)
Age at alloSCT (years)		
Median	66	63
Range	54-71	60-67
Median HCT-CI (Range)	1 (0 – 5)	0 (0 – 4)
Disease		
MDS	4 (50%)	2 (40%)
AML	4 (50%)	3 (60%)
Prior lines of treatment		
One	4 (50%)	3 (60%)
Two	4 (50%)	2 (40%)
Donor source		
Unrelated donor	4 (50%)	4 (80%)
Matched related donor	2 (25%)	1 (20%)
Haploidentical	2 (25%)	0
Conditioning regimen (intensity)		
Busulfan and fludarabine (MAC)	1 (12.5%)	0
Busulfan and fludarabine (RIC)	2 (25%)	2 (40%)
Fludarabine and melphalan (RIC)	3 (37.5)	3 (60%)
Fludarabine, cyclophosphamide and TBI (RIC)	2 (25%)	0
GVHD prophylaxis		
PTCY based	2 (25%)	2 (40%)
Tacrolimus-methotrexate	6 (75%)	3 (60%)
Acute GVHD		
Grade 2-4	4 (50%)	3 (60%)
Grade 3-4	1 (12.5%)	1 (20%)
Chronic GVHD		
Mild	0	0
Moderate	3 (37.5%)	1 (20%)
Severe	0	1 (20%)
Relapse	1 (12.5%)	0
Abbreviations: MAC: Myeloablative conditioning, PTCY: Post-transplant cyclophosphamide, RIC: Reduced intensity conditioning, TBI: Total body irradiation.		